07:00 , Mar 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Dedicator of cytokinesis 5 (DOCK5)

Musculoskeletal disease INDICATION: Osteoporosis In vitro and mouse studies suggest a DOCK5 inhibitor could help treat osteoporosis. DOCK5 has been implicated in osteoclast activity and bone resorption. In vitro, C21, a small molecule inhibitor of bone resorption,...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

MethylGene preclinical data

MethylGene announced results of a study suggesting that an antisense compound targeted to suppress a mouse DNA methyltransferase gene inhibits cancer growth in animals. Because methylation is a method cells use to turn off...
07:00 , May 28, 2012 |  BioCentury  |  Finance

AbbVie earlier

AbbVie earlier Early stage investorAbbott Biotech Ventures will start investing even earlier after parent company Abbott Laboratories (NYSE:ABT) splits in two, the firm's head of venture investment, Steven Kuemmerle, said at last week's C21 BioVentures conference...
07:00 , May 28, 2012 |  BioCentury  |  Finance

Carried away

Carried away Three out of four corporate VCs on a panel at last week's C21 BioVentures conference in Napa, Calif., said their compensation does not include carried interest. Any upside stays with the funds, which could...
07:00 , Apr 13, 2009 |  BioCentury  |  Finance

Ebb & Flow

In its $31 million financing this month, Savient Pharmaceuticals Inc. (NASDAQ:SVNT) employed a novel warrant structure that allowed it to finance ahead of a significant binary event without having to provide an upfront premium based...
07:00 , Jul 21, 2008 |  BioCentury  |  Finance

Ebb & Flow

In the largest untranched biotech financing this year, genome sequencing company Pacific Biosciences (formerly Nanofluidics) raised $100 million last week in a series E round. The company now has raised $178 million since it was...
07:00 , May 26, 2008 |  BioCentury  |  Finance

Ebb & Flow

Based on its track record of exits from its BioDiscovery 1 and 2 funds during the last eight years, Edmond de Rothschild Investment Partners has raised a new E150 million ($233.8 million) fund in less...